Top Story

FDA approves Adlyxin for type 2 diabetes

July 28, 2016

The FDA has approved the once-daily glucagon-like peptide-1 receptor agonist Adlyxin, a once-daily injection to improve glycemic control along with diet and exercise in adults with type 2 diabetes, Sanofi announced in a press release.

"The approval of Adlyxin reaffirms our continued commitment to addressing the challenges faced by people living with diabetes when trying to reach and maintain their individual blood glucose (HbA1c) targets," Peter Guenter, executive vice president and head of the global diabetes and cardiovascular business unit at Sanofi, said in the release. "We are pleased with this approval, as it offers us the opportunity to continue helping patients treated with basal insulin who remain uncontrolled."

In the Journals

Use of EHRs, CPOE associated with physician burnout, dissatisfaction

July 27, 2016
Physicians reported low satisfaction with their electronic health records and computerized physician order entry, according to findings published in Mayo Clinic
Health Care Legislative and Regulatory Update

Are the holiday baskets really worth the risk?

July 27, 2016
From international law firm Arnold & Porter LLP comes a timely column that provides views on current regulatory and legislative topics that weigh on the minds of…
In the Journals Plus

Health-related quality of life lower in parents of children with metabolic disease

July 27, 2016
Parents of children with congenital disorders of metabolism tend to have a lower health-related quality of life vs. parents of children without metabolic disease, with…
In the Journals Plus

Thyroid imaging identifies cancer recurrence, may not increase survival

July 27, 2016
Recurrence of thyroid cancer may be identified with more imaging, but imaging may not increase survival rates, recent findings show. “Despite a known rise in the…
More News Headlines »

New Treatment Paradigms for Diabetic Retinopathy: Current Status and Applications for Practice

This activity is supported by an educational grant from Genentech, Inc.

Despite a number of effective treatment options, diabetic eye disease is a leading cause of vision loss in the United…
More »
Meeting News Coverage

VIDEO: Results of LEADER trial provide “robust demonstration” of cardiovascular event reduction in high-risk type 2 diabetes

July 1, 2016
More »
Highlights from AACE

Highlights from AACE


Diabetic Retinopathy: The Importance of Early Screening, Referral, and Management

This activity is supported by an educational grant from Regeneron Pharmaceuticals, Inc.

Diabetic eye disease is one of the most common causes of vision loss in the United States. As the rates of diabetes…
More »
Current Issues
View the Current Issues